|Acute Kidney Injury (AKI)||Anemia|
|Chronic Kidney Disease (CKD)||Contrast Nephropathy|
|Cardiovascular Disease (CVD)||Diabetes|
|Lupus Nephritis||Peritoneal Dialysis|
Cystic kidney disease is associated with a greatest likelihood of progressing to end-stage renal disease, but the small risk of death.
Alvimopan also was found to shorten hospital length of stay.
Benefits observed for moderate consumption, but risk is increased for heavy consumption.
It is associated with fewer positive surgical margins and reduced need for additional treatment.
Increasing health insurance coverage and access to usual source of care necessary to meet targets.
Lower risk with no increase in bleeding regardless of CKD severity.
Switching from intravenous to oral alfacalcidol resulted in greater PTH suppression in patients with secondary hyperparathyroidism.
Findings support expanded clinical use of this simple measurement.
Low prepregnancy concentrations associated with increased risk of gestational diabetes.
Ferumoxytol and iron sucrose have comparable safety in the treatment of anemia in patients with CKD.
In a trial, more patients taking sildenfail citrate than placebo daily had functional erections at 24 months.
Increased risk of serious fall injuries is particularly high in those with previous fall injuries.
Full lipid profiles are recommended for all patients with chronic kidney disease at first presentation.
Complications other than urinary incontinence or erectile dysfunction occur frequently following treatment for PCa.
Blood loss is reduced and hospital stays are shorter compared with retropubic radical prostatectomy, but oncologic outcomes are similar.